

Client

Gurugram

Pathkind Diagnostics Pvt. Ltd.

Plot No. 55-56, Udhyog Vihar Ph-IV, Gurugram - 122015

Processed By

Pathkind Diagnostics Pvt. Ltd.

Plot No. 55-56, Udhyog Vihar Ph-IV, Gurugram - 122015

Name : Mrs. CL80 Billing Date 07/07/202312:19:52 : 35 Yrs Sample Collected on 10/07/2023 10:01:31 Age Sample Received on 10/07/2023 11:02:13 Sex : Female : P1000100012695 Report Released on P. ID No. 15/07/2023 11:00:01 : 10002304751 Accession No Barcode No. 10002304751-01

Referring Doctor: Self

Referred By Ref no.

Report Status - Final

Test Name	Result	Biological Ref. Interval	Unit
	BIOCHEMIS	STRY	
Hormone Levels: LH, FSH & PRL			
Follicle-Stimulating Hormone (FSH) Sample: Serum Method: ECLIA	4.56	Follicular Phase : 3.5 - 12.5 Ovulatory Phase : 4.7 - 21.5 Luteal Phase : 1.7 - 7.7 Postmenopausal : 25.8 - 134.8	mIU/mL
Luteinizing Hormone (LH) Sample: Serum Method: ECLIA	12.0	Follicular Phase : 2.4 - 12.6 Ovulatory Phase : 14.0 - 96.0 Luteal Phase : 1.0 - 11.4 Postmenopausal : 7.7 - 59.0	mIU/mL
Prolactin (PRL)	20.0	6.0 - 29.9	ng/mL

Follicle-Stimulating Hormone (FSH)

Clinical Significance:

Sample: Serum Method: ECLIA

FSH levels are raised In both males and females in primary hypogonadism.,primary gonadal failure, Complete testicular feminization syndrome, Precocious puberty and Menopause. Normal or decreased FSH are seen in Polycystic ovary disease.

Luteinizing Hormone (LH)

Clinical Significance:

Lutenizing Hormone (LH) levels are raised in both males and females in primary hypogonadism, menopause, Complete testicular feminization syndrome, Precocious puberty, Primary ovarian hypodysfunction in females and Polycystic ovary disease in females. LH is decreased in Primary ovarian hyperfunction in females, Primary hypergonadism in males and in both males and females in failure of the pituitary or hypothalamus.

Prolactin (PRL)







Client

Gurugram

Pathkind Diagnostics Pvt. Ltd.

Plot No. 55-56, Udhyog Vihar Ph-IV, Gurugram - 122015

Processed By Pathkind Diagnostics Pvt. Ltd.

Plot No. 55-56, Udhyog Vihar Ph-IV, Gurugram - 122015

Name : Mrs. CL80 Billing Date 07/07/202312:19:52 : 35 Yrs Age Sample Collected on 10/07/2023 10:01:31 10/07/2023 11:02:13 Sex : Female Sample Received on P. ID No. : P1000100012695 Report Released on 15/07/2023 11:00:01 : 10002304751 Barcode No. 10002304751-01 Accession No

Referring Doctor: Self

Referred By : Ref no. :

Report Status - Final

	-		
Test Name	Result	Biological Ref. Interval	Unit

- 1. Prolactin is secreted in a pulsatile manner and is also influenced by a variety of physiologic stimuli, it is recommended to test pooled sample ie 3 specimens at 20-30 minute intervals.
- 2. Major circulating form of Prolactin is a nonglycosylated monomer, but several forms of Prolactin linked with immunoglobulin occur which can give falsely high Prolactin results.
- 3. Macroprolactin assay is recommended if prolactin levels are elevated, but signs and symptoms of hyperprolactinemia are absent or pituitary imaging studies are normal

Clinical Use

- * Diagnosis & management of pituitary adenomas
- * Differential diagnosis of male & female hypogonadism

Increased Levels

- * Physiologic: Sleep, stress, postprandially, pain, coitus, pregnancy, nipple stimulation or nursing
- * Systemic disorders: Chest wall or thoracic spinal cord lesions, Primary / Secondary hypothyroidism, Adrenal insufficiency, Chronic renal failure, Cirrhosis
- * Medications:
 - * Psychiatric medications like Phenothiazine, Haloperidol, Risperidone, Domperidone, Fluoexetine, Amitriptylene, MAO inhibitors etc.,
 - * Antihypertensives: Alphamethyldopa, Reserpine, Verapamil
 - * Opiates: Heroin, Methadone, Morphine, Apomorphine
 - * Estrogens
 - * Oral contraceptives
 - * Cimetidine / Ranitidine
- * Prolactin secreting pituitary tumors: Prolactinoma, Acromegaly
- * Miscellaneous: Polycystic ovarian disease, Epileptic seizures, Ectopic secretion of prolactin by non-pituitary tumors, pressure / transaction of pituitary stalk, macroprolactinemia
- * Idiopathic

Decreased levels

- * Pituitary deficiency: Pituitary necrosis / infarction
- * Bromocriptine administration
- * Pseudohypoparathyroidism

** End of Report**

Dr. Aarti Khanna Nagpal

Senior Consultant

10002304751 Mrs. CL80

Page No: 2 of 2





